Securities Times e Company Newsroyalflushpoker, May 24royalflushpoker, Yunhe Pharmaceutical (Tianjin) Co., Ltd.(referred to as "Yunhe Pharmaceutical"), a wholly-owned subsidiary of Yunnan Baiyao (000538), the Phase I/IIa clinical trial of the innovative nuclear drug INR101 injection, was completed at Beijing Friendship Hospital Affiliated to Capital Medical University. The first healthy subject was enrolled and administered. INR101 injection is an innovative chemical Class 1 radiologic diagnostic drug developed by Yunhe Pharmaceutical. It is suitable for PET imaging of PSMA positive lesions in prostate cancer patients.
